Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands
AssigneeWyeth
InventorsPing Zhou, Michael Gerard Kelly, Yanfang Li
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. 1
Claims20
A compound of formula I
- 26
- wherein
- Q is SO2, CO, CONR24, CSNR25 or CH2;
- W is N or CR2;
- X is N or CR9;
- Y is NR or CR10R29;
- Z is NR21 or CR11R30 with the proviso that when Y is NR then Z must be CR11LR30 and with the further proviso that at least one of Y and Z must be NR or NR21;
- n is 0 or an integer of 1 or 2;
- R and R21 are each independently H, CNR26NR27R28 or a C1-C6alkyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
- R1, R2 and R9 are each independently H, halogen, CN, OCO2R12, CO2R13, CONR22R23, CNR14NR15R16 SOmR17 NR18R19, OR20 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6-cycloalkyl, cycloheteroalkyl, C1-C6alkanoyl, aryl or heteroaryl group each optionally substituted;
- m is 0 or an integer of 1 or 2;
- R3 and R4 are each independently H, halogen, C1-C4alkyl or C1-C4haloalkyl or R3 and R4 may be taken together with the atom to which they are attached to form a carbonyl group;
- R5 and R6 are each independently H or an optionally substituted C1-C6alkyl group;
- R7 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, aryl or heteroaryl group each optionally substituted;
- R8 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
- R10, R11, R29 and R30 are each independently H or an optionally substituted C1-C6alkyl group;
- R12, R13 and R17 are each independently H or an optionally substituted C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group;
- R14, R15, R16, R18, R19, R26, R27 and R28 are each independently H or C1-C4alkyl;
- R20, R22 and R23 are each independently H or an optionally substituted C1-C6alkyl group;
- R24 and R25 are each independently H or an alkyl, aryl or heteroaryl group each optionally substituted;
- and
- ---- represents a single bond or a double bond;
- or
- a pharmaceutically acceptable salt thereof.
A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing said patient with a therapeutically effective amount of a compound of formula I
- 27
- wherein
- Q is SO2, CO, CONR24, CSNR25 or CH2;
- W is N or CR7;
- X is N or CR9;
- Y is NR or CR10R29;
- Z is NR21 or CR11R30 with the proviso that when Y is NR then Z must be CR11R30 and with the further proviso that at least one of Y and Z must be NR or NR21;
- n is 0 or an integer of 1 or 2q;
- R and R21 are each independently H, CNR26NR27R28, or a C1-C6alkyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
- R1, R2 and R9 are each independently H, halogen, CN, OCO2R12, CO2R13, CONR22R23, CNR14NR15R16, SOmR17, NR18R19OR20, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6-cycloalkyl, cycloheteroalkyl, C1-C6alkanoyl, aryl or heteroaryl group each optionally substituted;
- m is 0 or an integer of 1 or 2;
- R3 and R4 are each independently H, halogen, C1-C4alkyl or C1-C4haloalkyl or R3 and R4 may be taken together with the atom to which they are attached to form a carbonyl group;
- R5 and R6 are each independently H or an optionally substituted C1-C6alkyl group;
- R7 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, aryl or heteroaryl group each optionally substituted;
- R8 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
- R10, R11, R29 and R30 are each independently H or an optionally substituted C1-C6alkyl group;
- R12, R13 and R17 are each independently H or an optionally substituted C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group;
- R14, R15, R16, R18, R19, R26, R27 and R28 are each independently H or C1-C4alkyl;
- R20, R22 and R23 are each independently H or an optionally substituted C1-C6alkyl group;
- R24 and R25 are each independently H or an alkyl, aryl or heteroaryl group each optionally substituted;
- and
- ---- represents a single bond or a double bond;
- or
- a pharmaceutically acceptable salt thereof.
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I
- 28
- wherein
- Q is SO2, CO, CONR24, CSNR25 or CH2;
- W is N or CR7;
- X is N or CR9;
- Y is NR or CR10R29;
- Z is NR21 or CR11R30 with the proviso that when Y is NR then Z must be CR1LR30 and with the further proviso that at least one of Y and Z must be NR or NR21;
- n is 0 or an integer of 1 or 2;
- R and R21 are each independently H, CNR26NR27R28, or a C1-C6alkyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
- R1, R2 and R9 are each independently H, halogen, CN, OCO2R12, CO2R13, CONR22R23, CNR14NR15R16, SOmR17, NR18R19, OR20, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6-cycloalkyl, cycloheteroalkyl, C1-C6alkanoyl, aryl or heteroaryl group each optionally substituted;
- m is 0 or an integer of 1 or 2;
- R3 and R4 are each independently H, halogen, C1-C4alkyl or C1-C4haloalkyl or R3 and R4 may be taken together with the atom to which they are attached to form a carbonyl group;
- R5 and R6 are each independently H or an optionally substituted C1-C6alkyl group;
- R7 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, aryl or heteroaryl group each optionally substituted;
- R8 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
- R10, R11, R29 and R30 are each independently H or an optionally substituted C1-C6alkyl group;
- R12, R13 and R1, are each independently H or an optionally substituted C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group;
- R14, R15, R16, R18, R19, R26, R27 and R28 are each independently H or C1-C4alkyl;
- R20, R22 and R23 are each independently H or an optionally substituted C1-C6alkyl group;
- R24 and R25 are each independently H or an alkyl, aryl or heteroaryl group each optionally substituted;
- and
- ---- represents a single bond or a double bond;
- or
- a pharmaceutically acceptable salt thereof.
A process for the preparation of a compound of formula Ia′
- 29
- wherein
- W is N or CR7;
- X is N or CR9;
- R1, R2 and R9 are each independently H, halogen, CN, OC2R12, CO2R13, CONR22R23, CNR14NR15R16, SOmR17, NR18R19, OR20, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, C1-C6alkanoyl, aryl or heteroaryl group each optionally substituted;
- m is 0 or an integer of 1 or 2;
- R7 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, aryl or heteroaryl group each optionally substituted;
- R8 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
- R12, R13 and R17 are each independently H or an optionally substituted C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group;
- R14, R15, R16, R18, R19, R26, R27 and R28 are each independently H or C1-C4 alkyl;
- and
- R21 is H, CNR26NR27R28, or a C1-C6alkyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted
- which process comprises reacting a compound of formula IVa
- 30
- wherein G represents a protecting group and W, X, R1 and R2 are as defined hereinabove with an arylsulfonyl chloride, R8SO2Cl, wherein R8 is as defined hereinabove in the presence of a base to form the intermediate of formula Va;
- 31
- deprotecting the formula Va compound in the presence of an acid to give the compound of formula Ia′ wherein R2, is H;
- and optionally reacting said formula Va compound with an alkylating agent, R21-Hal, wherein Hal is Cl, I or Br and R21 is other than H.
Dependencies are inferred from the claim text.